PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone...

PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth
Hormone and Longer-Acting Erythropoietin

NES-ZIONA, Israel, June 30 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (OTC
Bulletin Board: PBTH), formerly Modigene Inc., today announced that the U. S.
Patent and Trademark Office (PTO) has issued two new patents for the company's
long-acting CTP-enhanced human growth hormone (hGH-CTP) and human
erythropoietin (EPO-CTP). The patents cover the composition of PROLOR's
proprietary pharmaceutical compounds as well as certain associated methods.
PROLOR's CTP technology is based on a short amino acid sequence, the Carboxyl
Terminal Peptide that occurs naturally in humans. When attached to a
therapeutic protein, CTP extends the time that the protein is active in the
body.

"These two new patents covering CTP-enhanced human growth hormone and
erythropoietin represent another significant layer of protection within our
CTP-based intellectual property portfolio," said Shai Novik, president of
PROLOR. "We have also filed several other patent applications for additional
CTP-enhanced long-acting therapeutic proteins and peptides that are currently
pending. We are confident that our growing CTP patent estate will provide
excellent protection for both our compounds under development and for our
innovative and versatile platform technology, and we believe it will serve as
an important value driver for PROLOR in the future."

The potential utility of the CTP technology has been demonstrated by
Schering-Plough, which is developing the technology for fertility applications
only. Data from its Phase III ENGAGE trial demonstrated that women receiving
a single injection of the fertility drug FSH-CTP achieved the same pregnancy
rates as women receiving seven consecutive daily injections of commercial FSH.
This 1,509 patient trial, which was the largest double-blind fertility trial
ever conducted, formed the basis for a Marketing Authorization Application by
Schering-Plough that is under review by the European Medicines Agency.

PROLOR is using the same CTP technology to extend the duration of action of
other therapeutic proteins. CTP was discovered at Washington University in
St. Louis, which has exclusively licensed rights for the use of CTP with all
therapeutic proteins to PROLOR, with the exception of four endocrine hormones
licensed to Schering-Plough. PROLOR plans to initiate human clinical trials
with hGH-CTP, its longer-acting version of human growth hormone, later this
year.

The issue date for U.S. Patents 7,553,940 (hGH-CTP) and 7,553,941 (EPO-CTP) is
June 30, 2009.

ABOUT PROLOR BIOTECH
PROLOR Biotech, Inc. is a biopharmaceutical company applying its patented CTP
technology to develop longer-acting, proprietary versions of already approved
therapeutic proteins that currently generate billions of dollars in annual
global sales. The CTP technology is applicable to virtually all proteins and
PROLOR is currently developing long-acting versions of human growth hormone,
interferon beta and erythropoietin, which are in late preclinical development,
as well as GLP-1. For more information on PROLOR, visit
http://www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking
statements, including statements regarding the results of current studies and
preclinical experiments and the effectiveness of PROLOR's long-acting protein
programs, which are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Investors are cautioned that
forward-looking statements involve risks and uncertainties that may affect
PROLOR's business and prospects, including the risks that PROLOR may not
succeed in developing any commercial products based upon its long-acting
protein technology, including any long-acting versions of human growth
hormone, erythropoietin, interferon beta or GLP-1; that the long-acting
products in development may fail, may not achieve the expected results or
effectiveness and/or may not generate data that would support the approval or
marketing of these products for the indications being studied or for other
indications; that ongoing studies may not continue to show substantial or any
activity; that the actual dollar amount of any grants from the OCS is
uncertain and is subject to policy changes of the Israeli government, and that
such grants may be insufficient to assist with product development; and other
risks and uncertainties that may cause results to differ materially from those
set forth in the forward-looking statements. The development of any products
using the CTP platform technology could also be affected by a number of other
factors, including unexpected safety, efficacy or manufacturing issues,
additional time requirements for data analyses and decision making, the impact
of pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by
competitors and other third parties. In addition to the risk factors set forth
above, investors should consider the economic, competitive, governmental,
technological and other factors discussed in PROLOR's filings with the
Securities and Exchange Commission.

PROLOR CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
PROLOR Biotech, Inc. GendeLLindheim BioCom Partners
Tel: +1 866 644-7811 +1 212 918-4650
Email: shai@modigeneinc.com

SOURCE PROLOR Biotech, Inc.

Shai Novik, President of PROLOR Biotech, Inc., 1-866-644-7811,
shai@modigeneinc.com; or Barbara Lindheim of GendeLLindheim BioCom Partners,
+1-212-918-4650, for PROLOR Biotech, Inc.